Vercise™ DBS Dystonia Prospective Study
← catalyst calendarNCT02686125 · readout ≤ 1,595 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
36
Countries
Belgium, Canada, Germany +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-03-07 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2016-02-19 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dystonia
Intervention
- Device: Deep Brain Stimulation (DBS) — also filed as Vercise DBS System Boston Scientific
Primary outcomes
what the primary-completion date above is the date OFProportion of subjects with reduction in dystonia symptoms as assessed by BFMDRS score
measured up to 3 years
Proportion of cervical dystonia subjects with reduction in symptoms as assessed by TWSTRS score
measured up to 3 years
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed